- Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to ...
INOVIO , a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced ...
Like other DNA medicines, INO-3107 has shown the ability to generate antigen-specific T cells that is not affected by anti-vector immunity impacting immunogenicity ... the FDA's accelerated approval ...
Today's businesses rely on effective end-to-end processes for consistently satisfying consumer and market needs. Achieving such corporate transitions successful ...
The tourism industry remains one of the most influential sectors in the world economy, supporting millions of jobs and generating trillions in revenue. Yet, behind its growth lies a web of suppliers, ...
Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2025 and the completion of ESSENCE, its global, Phase ...
Early-stage lung adenocarcinoma alters DNA methylation, mRNA transcription, and protein expression in adjacent tissues, exhibiting either steep changes at the tumor boundaries or shallow changes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback